Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE -

Sponsor
Research Center Borstel
Study ID
NCT07386912
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Asthma
  • Bacterial Pneumonia
  • COPD
  • Tuberculosis
  • Viral Pneumonia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Characterization of the neutrophil granulocyte epigenome — OTHER
    Characterization of epigenomic differences in neutrophils from patients with different lung diseases (asthma, COPD, pneumonia, tuberculosis, and viral pulmonary infections such as COVID-19 and influenza) by identifying disease-specific epigenetic and functional signatures
  • Characterization of the T-cell immune response to to various oxidatively modified mycobacterial antigens — OTHER
    Investigation of the response (activation/stimulation) of antigen-specific T cells from patients with tuberculosis to various oxidatively modified mycobacterial antigens, with the aim of determining whether changes in the redox status of these antigens measurably influence the adaptive immune response.

Study Details

The OXIGENE study is a research project that aims to better understand how the immune system behaves in people with lung diseases such as asthma, COPD, pneumonia, tuberculosis, and viral lung infections. By analyzing a single blood sample, the study examines how certain immune cells react during inflammation and infection, and whether lasting changes in these cells influence how strongly the body responds to disease. Although participants do not receive direct medical benefit, the results may help improve future diagnosis and treatment of lung diseases by providing deeper insight into immune responses.

Key Dates

First listed
Feb 4, 2026
Start date
Feb 1, 2026
Status verified
Jan 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2030

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Asthma
    Patients with Asthma
  • Arm: COPD
    Patients with chronic obstructive pulmonary disease
  • Arm: Viral pneumonia
    Patients suffering from viral pneumonia, e.g. COVID-19 or Influenza
  • Arm: Bacterial pneumonia
    Patients suffering from bacterial pneumonia
  • Arm: Tuberculosis
    Patients treated for tuberculosis

Primary Outcome Measure

Characterization of the neutrophil granulocyte epigenome [ Time Frame: 2030 ]

Central Contacts

Find similar trials

Nationwide
Asthma trialsCOPD trialsPulmonology trialsLung disease trials

Related Studies